03B4
Describe how a computer-controlled infusion device targets and maintains constant blood concentrations of propofol.
33%
03A2
Outline the neuropharmacology of thiopentone, covering only its site of action, EEG changes, effects on cerebral blood flow and intracranial pressure.
80%
02A16
Briefly outline the pharmacology of flumazenil
45%
02A11
Briefly outline the effects of thiopentone and ketamine not mediated via the central nervous system.
77%
01B9
What do you understand by the term "clearance". Using propofol as an example, explain briefly the importance of clearance.
77%
01A13
Outline the NON-ideal features as an intravenous induction agent of the current formulations of propofol
55%
00B14
Write short notes contrasting the cardiovascular effects of propofol and ketamine seen clinically
46%
99B14
Briefly outline the actions of intravenous induction agents not mediated via the central nervous system.
24%
99A13
Describe the neuropharmacology of thiopentone covering its site of action, EEG changes, effects on cerebral blood flow and intracranial pressure.
78%
98B9
Write short notes contrasting the cardiovascular effects of propofol and ketamine seen clinically.
63%
98A10
Outline the NON-ideal features as an intravenous induction agent of the current preparation of propofol.
67%
1997
List the properties of an ideal intravenous anaesthetic. To what extent does methohexitone conform to this ideal.
76%
95A9
Briefly outline the effects of intravenous induction agents not mediated via the central nervous system, as well as their side effects. Include a brief account of the mechanisms by which these side effects are exerted
17%
1994
Describe the ideal intravenous anaesthetic agent. Describe in detail the extent to which propofol approaches this ideal.
1993
Briefly explain how knowledge of the pharmacokinetic properties of propofol would enable it to be used for the induction and maintenance of anaesthesia by continuous infusion.
1992
Write short notes on Methohexitone
1991
Write short notes on Methohexitone
1990
Write short notes on the pharmacokinetics of midazolam